Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review Article
  • Published:

Mechanisms of Disease: prostate cancer—a model for cancer chemoprevention in clinical practice

Nature Clinical Practice Oncology volume 2, pages 255–261 (2005)Cite this article

Abstract

Prostate cancer is a significant cause of cancer death, making it an attractive target for chemoprevention. Epidemiologic studies and the Prostate Cancer Prevention Trial indicate that chemoprevention is possible. Strategies for prevention include hormonal manipulation and limiting accumulation of genetic damage with anti-inflammatory agents and/or dietary antioxidants. Development of an effective chemoprevention strategy for prostate cancer is evolving and will likely serve as a model for chemoprevention of other adult malignancies.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Prostaglandin synthesis and possible implications for prostate carcinogenesis.

Similar content being viewed by others

References

  1. Jemal A et al. (2004) Cancer statistics, 2004. CA Cancer J Clin 54: 8–29

    Article  Google Scholar 

  2. Huggins C and Hodges CV (1941) Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatiac carcinoma of the prostate. Cancer Res 1: 293–297

    CAS  Google Scholar 

  3. Steers WD (2001) 5alpha-reductase activity in the prostate. Urology 58: 17–24; discussion 24

    Article  CAS  Google Scholar 

  4. Andriole G et al. (2004) Dihydrotestosterone and the prostate: the scientific rationale for 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia. J Urol 172: 1399–1403

    Article  CAS  Google Scholar 

  5. Walsh PC et al. (1974) Familial incomplete male pseudohermaphroditism, type 2. Decreased dihydrotestosterone formation in pseudovaginal perineoscrotal hypospadias. N Engl J Med 291: 944–949

    Article  CAS  Google Scholar 

  6. Imperato-McGinley J and Zhu YS (2002) Androgens and male physiology the syndrome of 5alpha-reductase-2 deficiency. Mol Cell Endocrinol 198: 51–59

    Article  CAS  Google Scholar 

  7. Imperato-McGinley J et al. (1992) Prostate visualization studies in males homozygous and heterozygous for 5 alpha-reductase deficiency. J Clin Endocrinol Metab 75: 1022–1026

    CAS  PubMed  Google Scholar 

  8. Wilson JD and Roehrborn C (1999) Long-term consequences of castration in men: lessons from the Skoptzy and the eunuchs of the Chinese and Ottoman courts. J Clin Endocrinol Metab 84: 4324–4331

    Article  CAS  Google Scholar 

  9. Wu AH et al. (1995) Serum androgens and sex hormone-binding globulins in relation to lifestyle factors in older African-American, white, and Asian men in the United States and Canada. Cancer Epidemiol Biomarkers Prev 4: 735–741

    CAS  PubMed  Google Scholar 

  10. Hsing AW et al. (2000) International trends and patterns of prostate cancer incidence and mortality. Int J Cancer 85: 60–67

    Article  CAS  Google Scholar 

  11. Makridakis NM and Reichardt JK (2004) Molecular epidemiology of androgen-metabolic loci in prostate cancer: predisposition and progression. J Urol 171 (Suppl): S25–S28; discussion S28–S29

    CAS  PubMed  Google Scholar 

  12. Thompson IM et al. (2003) The influence of finasteride on the development of prostate cancer. N Engl J Med 349: 215–224

    Article  CAS  Google Scholar 

  13. Feigl P et al. (1995) Design of the Prostate Cancer Prevention Trial (PCPT). Control Clin Trials 16: 150–163

    Article  CAS  Google Scholar 

  14. Andriole G et al. (2004) Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial. J Urol 172: 1314–1317

    Article  CAS  Google Scholar 

  15. Coussens LM and Werb Z (2002) Inflammation and cancer. Nature 420: 860–867

    Article  CAS  Google Scholar 

  16. Zha S et al. (2004) Cyclooxygenases in cancer: progress and perspective. Cancer Lett 215: 1–20

    Article  CAS  Google Scholar 

  17. DeWitt DL and Smith WL (1988) Primary structure of prostaglandin G/H synthase from sheep vesicular gland determined from the complementary DNA sequence. Proc Natl Acad Sci U S A 85: 1412–1416

    Article  CAS  Google Scholar 

  18. Hla T and Neilson K (1992) Human cyclooxygenase-2 cDNA. Proc Natl Acad Sci U S A 89: 7384–7388

    Article  CAS  Google Scholar 

  19. Pruthi RS et al. (2003) Cyclooxygenase-2 as a potential target in the prevention and treatment of genitourinary tumors: a review. J Urol 169: 2352–2359

    Article  CAS  Google Scholar 

  20. Nagano S et al. (2002) Molecular mechanisms of lipopolysaccharide-induced cyclooxygenase-2 expression in human neutrophils: involvement of the mitogen-activated protein kinase pathway and regulation by anti-inflammatory cytokines. Int Immunol 14: 733–740

    Article  CAS  Google Scholar 

  21. Chan TA et al. (1998) Mechanisms underlying nonsteroidal antiinflammatory drug-mediated apoptosis. Proc Natl Acad Sci U S A 95: 681–686

    Article  CAS  Google Scholar 

  22. Leng J et al. (2003) Cyclooxygenase-2 promotes hepatocellular carcinoma cell growth through Akt activation: evidence for Akt inhibition in celecoxib-induced apoptosis. Hepatology 38: 756–768

    Article  CAS  Google Scholar 

  23. Gately S (2000) The contributions of cyclooxygenase-2 to tumor angiogenesis. Cancer Metastasis Rev 19: 19–27

    Article  CAS  Google Scholar 

  24. Yu HG et al. (2003) Increased abundance of cyclooxygenase-2 correlates with vascular endothelial growth factor-A abundance and tumor angiogenesis in gastric cancer. Cancer Lett 195: 43–51

    Article  CAS  Google Scholar 

  25. De Marzo AM et al. (2003) Human prostate cancer precursors and pathobiology. Urology 62: 55–62

    Article  Google Scholar 

  26. De Marzo AM et al. (1999) Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am J Pathol 155: 1985–1992

    Article  CAS  Google Scholar 

  27. Giardiello FM et al. (2002) Primary chemoprevention of familial adenomatous polyposis with sulindac. N Engl J Med 346: 1054–1059

    Article  CAS  Google Scholar 

  28. Giardiello FM (1994) Sulindac and polyp regression. Cancer Metastasis Rev 13: 279–283

    Article  CAS  Google Scholar 

  29. Asano TK and McLeod RS (2004) Non steroidal anti-inflammatory drugs (NSAID) and Aspirin for preventing colorectal adenomas and carcinomas. The Cochrane Database of Systematic Reviews, Issue 2, Art. No CD004079

    Google Scholar 

  30. Garcia Rodriguez LA and Huerta-Alvarez C (2000) Reduced incidence of colorectal adenoma among long-term users of nonsteroidal antiinflammatory drugs: a pooled analysis of published studies and a new population-based study. Epidemiology 11: 376–381

    Article  CAS  Google Scholar 

  31. Moran EM (2002) Epidemiological and clinical aspects of nonsteroidal anti-inflammatory drugs and cancer risks. J Environ Pathol Toxicol Oncol 21: 193–201

    Article  CAS  Google Scholar 

  32. Roberts RO et al. (2002) A population-based study of daily nonsteroidal anti-inflammatory drug use and prostate cancer. Mayo Clin Proc 77: 219–225

    Article  Google Scholar 

  33. Nelson JE and Harris RE (2000) Inverse association of prostate cancer and non-steroidal anti-inflammatory drugs (NSAIDs): results of a case-control study. Oncol Rep 7: 169–170

    CAS  PubMed  Google Scholar 

  34. Couzin J (2004) Drug safety. Withdrawal of Vioxx casts a shadow over COX-2 inhibitors. Science 306: 384–385

    Article  CAS  Google Scholar 

  35. [No authors listed] (2004) Vioxx: an unequal partnership between safety and efficacy. Lancet 364: 1287–1288

  36. Klein EA et al. (2003) The selenium and vitamin E cancer prevention trial. World J Urol 21: 21–27

    CAS  PubMed  Google Scholar 

  37. Klein EA (2004) Selenium: epidemiology and basic science. J Urol 171 (Suppl): S50–S53; discussion S53

    CAS  PubMed  Google Scholar 

  38. Zhuo H et al. (2004) Selenium and lung cancer: a quantitative analysis of heterogeneity in the current epidemiological literature. Cancer Epidemiol Biomarkers Prev 13: 771–778

    CAS  PubMed  Google Scholar 

  39. Duffield-Lillico AJ et al. (2002) Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: a summary report of the Nutritional Prevention of Cancer Trial. Cancer Epidemiol Biomarkers Prev 11: 630–639

    CAS  PubMed  Google Scholar 

  40. Ghadirian P (2000) A case-control study of toenail selenium and cancer of the breast, colon, and prostate. Cancer Detect Prev 24: 305–313

    CAS  PubMed  Google Scholar 

  41. Yoshizawa K et al. (1998) Study of prediagnostic selenium level in toenails and the risk of advanced prostate cancer. J Natl Cancer Inst 90: 1219–1224

    Article  CAS  Google Scholar 

  42. Blot WJ et al. (1993) Nutrition intervention trials in Linxian, China: supplementation with specific vitamin/mineral combinations, cancer incidence, and disease-specific mortality in the general population. J Natl Cancer Inst 85: 1483–1492

    Article  CAS  Google Scholar 

  43. Duffield-Lillico AJ et al. (2003) Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. BJU Int 91: 608–612

    Article  CAS  Google Scholar 

  44. Jiang Q et al. (2001) gamma-tocopherol, the major form of vitamin E in the US diet, deserves more attention. Am J Clin Nutr 74: 714–722

    Article  CAS  Google Scholar 

  45. Hensley K et al. (2004) New perspectives on vitamin E: gamma-tocopherol and carboxyelthylhydroxychroman metabolites in biology and medicine. Free Radic Biol Med 36: 1–15

    Article  CAS  Google Scholar 

  46. Longnecker MP et al. (1992) Serum alpha-tocopherol concentration in relation to subsequent colorectal cancer: pooled data from five cohorts. J Natl Cancer Inst 84: 430–435

    Article  CAS  Google Scholar 

  47. Yong LC et al. (1997) Intake of vitamins E, C, and A and risk of lung cancer. The NHANES I epidemiologic followup study. First National Health and Nutrition Examination Survey. Am J Epidemiol 146: 231–243

    Article  CAS  Google Scholar 

  48. Virtamo J et al. (2003) Incidence of cancer and mortality following alpha-tocopherol and beta-carotene supplementation: a postintervention follow-up. JAMA 290: 476–485

    Article  CAS  Google Scholar 

  49. Bermejo C et al. (2004) Localized prostate cancer: quality of life meets Whitmore's legacy. J Natl Cancer Inst 96: 1348–1349

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Urologic Oncology,

    Edith D Canby-Hagino & Ian M Thompson

  2. Department of Urology, at the University of Texas Health Science Center, San Antonio, TX, USA

    Edith D Canby-Hagino & Ian M Thompson

Authors
  1. Edith D Canby-Hagino
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ian M Thompson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Edith D Canby-Hagino.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Glossary

5α-REDUCTASE DEFICIENCY

In males, this results in ambiguous genitalia, pseudovaginal perineoscrotal hypospadias, fully differentiated (although sometimes undescended) testes, normal Wolffian ductal systems, and an underdeveloped prostate

Rights and permissions

Reprints and permissions

About this article

Cite this article

Canby-Hagino, E., Thompson, I. Mechanisms of Disease: prostate cancer—a model for cancer chemoprevention in clinical practice. Nat Rev Clin Oncol 2, 255–261 (2005). https://doi.org/10.1038/ncponc0172

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncponc0172

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing